Denali therapeutics reports second quarter 2025 financial results and business highlights

Tividenofusp alfa bla for hunter syndrome accepted for priority review and assigned pdufa target action date of january 5, 2026; company preparing for commercial launch dnl126 accelerated approval path for sanfilippo syndrome type a aligned with fda; phase 1/2 study nearing completion of enrollment; planning underway for a global phase 3 confirmatory study on track to submit regulatory applications in 2025 to begin clinical testing of one to two additional transportvehicletm (tv)-enabled programs preclinical research on atv:abeta program for alzheimer's disease published in the journal science south san francisco, calif., aug. 11, 2025 (globe newswire) -- denali therapeutics inc. (nasdaq: dnli) today reported financial results for the second quarter ended june 30, 2025, and provided business highlights.
DNLI Ratings Summary
DNLI Quant Ranking